Free Oncology CME

Includes eleven online, self-learning activities:

• The state of prostate cancer treatment: advances in approach for advanced disease –  (1 hr CE) ACCME ACPE MOC
• Ongoing challenges and optimal approaches in the management of metastatic colorectal cancer (mCRC) – (1 hr CE) ACCME ACPE MOC
• Advanced systemic mastocytosis: from recognition to treatment (Tsewang Tashi MD) – (1 hr CE) ACCME ACPE MOC
• Pancreatic Cancer: Updates from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting – (0.75 hr CE) ACCME ACPE MOC
• Metastatic urothelial carcinoma (mUC): Updates from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Waddah Arafat MD) – (0.75 hr CE) ACCME ACPE MOC
• Taking the next step in the management of relapsed or refractory follicular lymphoma (Eric Tam MD) – (1 hr CE) ACCME ACPE MOC
• Initial- and later-line treatment considerations in advanced renal cell carcinoma (RCC) – (1 hr CE) ACCME ACPE MOC
• Treatment considerations in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): evolving approaches to an evolving disease landscape – (1 hr CE) ACCME ACPE MOC
• Contemporary treatment approaches in the management of chronic graft-versus-host disease (GVHD) – (1 hr CE) ACCME ACPE MOC
• Hitting management strategies of metastatic nasopharyngeal carcinoma on the nose – (1 hr CE) ACCME ACPE MOC
• Advanced hepatocellular carcinoma (HCC) including updates from the European Society for Medical Oncology (ESMO) 2023 – (0.75 hr CE) ACCME ACPE MOC

Target Audience: HCPs including: medical oncologists, oncology surgeons, and pathologists; physicians assistants, nurse practitioners, and pharmacists specializing in oncology, hematology, gastroenterology, urology, with some overlap in otolaryngology, transplant medicine, allergy/immunology, nephrology, and hepatology

This brief accredited CME activity uses a quiz-based microlearning platform to present a patient case scenario and related questions, allowing clinicians to quickly test their knowledge of the essential components of evaluating patients with metastatic colorectal cancer to the liver and selecting an appropriate treatment strategy. They can then compare their responses with those of their peers. Rationale for correct answers and key educational takeaways are provided via video clips from expert faculty.

In this online, self-learning activity:

Chronic lymphocytic leukemia (CLL) is a disease in which leukemic cells accumulate in the peripheral blood, bone marrow, and lymphatic tissue. Elderly patients comprise the vast majority of those diagnosed with CLL with a mean patient age of 72 years. There are over 23,000 cases in the U.S. per year, with an annual mortality rate in excess of 4,400. CLL may have an indolent disease course and go undetected for some time. Patients may present clinically with a range of constitutional symptoms usually range from lymphadenopathy (the most common), night sweats, weight loss, weakness, and fever. Staging systems take into account a variety of factors, including lymphadenopathy, splenomegaly, hepatomegaly, and the presence and severity of cytopenias, while a patient’s prognosis is impacted by cytogenetic abnormalities and earlier progression of disease. Both the presentation and progression of CLL vary between patients, although patients with very-high-risk disease have a median survival of 19 months and a five-year overall survival of less than 24%.

In this MedX activity, Robert Haddad, MD, explores the latest clinical data for emerging novel therapies for recurrent/metastatic head and neck squamous cell carcinoma with an emphasis on results presented at ESMO 2025.

In this online, self-learning activity:

Lung cancer is the leading cause of cancer-related death in the United States, with more than 236,000 new cases diagnosed and over 124,000 deaths annually. The most common type of lung cancer, non–small cell lung cancer (NSCLC), accounts for about 85% of cases and has seen steady declines in mortality over the past several years as improvements have been made in diagnosis, staging, and treatment. In contrast, outcomes for the less prevalent small cell lung cancer (SCLC), which is neuroendocrine in nature and accounts for about 14% of all lung cancer cases, have remained poor in recent years despite improvement in those for NSCLC.

In this online, self-learning activity:

Polycythemia vera (PV) is an uncommon hematologic malignancy belonging to BCR-ABL1-negative myeloproliferative neoplasms (MPNs), characterized by activating mutations in JAK2 that cause the proliferation of malignant hematopoietic stem and progenitor cells. PV is characterized by erythrocytosis, thrombocytosis, leukocytosis, and splenomegaly, with approximately 50% of patients presenting symptoms such as fatigue, headache, visual disturbances, and pruritus at diagnosis. Others may be asymptomatic and diagnosed incidentally through blood tests, and as the disease progresses, individuals often experience worsening symptoms along with new ones, including early satiety and inactivity. Approximately 148,000 individuals in the United States have PV; the annual incidence of PV ranges from 0.01 to 2.61 per 100,000 individuals, while its prevalence varies from 45 to 57 per 100,000. Primarily affecting older individuals, PV has an overall median age of 61 years, with less than 10% of cases occurring in those under 40 years old.

In this online, self-learning activity:

Over 64,000 people develop and close 50,000 die each year of pancreatic cancer, and by 2030, pancreatic cancer is expected to surpass colorectal and breast cancer to become the second-leading cause of cancer death. Over 90% of whom have pancreatic ductal adenocarcinoma (PDAC), and while the 5-year survival rate for patients diagnosed with localized disease is over 44%, patients with locally advanced (LAPC) or metastatic disease have a median overall survival of 12 to 14 months. Symptoms associated with pancreatic cancer are not usually evident in the early stages of the disease and may be intermittent and nonspecific, and more than half of patients have advanced disease by the time they are diagnosed.

In this online, self-learning activity:

Nasopharyngeal carcinoma (NPC) is a rare form of head and neck cancer, with 133,000-176,000 new cases diagnosed worldwide each year. Although relatively uncommon in the United States with an age-standardized incidence rate of 0.41 per 100,000 population, NPC is endemic to certain geographic regions, such as southern China, Southeast Asia, and North Africa. Several risk factors for NPC have been identified, including consumption of salted fish, alcohol use, wood dust exposure, and plasma Epstein–Barr virus positivity.

In this online, self-learning activity:

Urothelial carcinoma (UC) is a cancer affecting both the bladder and beyond, including tumors of the upper urinary tract and proximal urethra. Cancers of the urinary tract affect more than 1.6 million people worldwide and collectively are the 6^th most common type of cancer in the US. UC itself accounts for over 84,000 new cases and 17,000 deaths each year. The five-year survival for noninvasive UC is 96%, but the five-year survival drops to eight percent for metastatic disease (mUC), suggesting there may be room for improvement in the management of the disease.

In this online, self-learning activity:

Renal cell carcinoma (RCC) is a cancer that develops in the nephrons. It is responsible for most cancers of the kidney and renal pelvis, which occur in close to 82,000 people and account for over 14,000 deaths in the U.S. annually. The five-year survival rate is 93% for patients with early stages of the disease. However, in patients with advanced or metastatic disease, the five-year survival is 17%, representing an area of ongoing clinical need.

In this online, self-learning activity:

Prostate cancer (PC) is the most common form of malignancy among men in the U.S. with close to 314,000 new cases and over 35,000 deaths from PC annually. Over the past few decades, the death rates associated with PC have declined, likely due to changes in screening practices and improved treatment options. However, the incidence of PC overall has increased in recent years, and the incidence of mPC at the time of diagnosis is on the rise, accounting for about 8% of those diagnosed. And while patients with local or regional disease have 5-year survival rates close to 100%, that number decreases to 37% for patients with metastatic disease (mPC). Mortality aside, as mPC advances, patients often experience increasing symptom burden, such as persistent fatigue and bone pain, both of which can severely impact their overall quality of life (QoL).